{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:28:52Z","timestamp":1787110132254,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82561160165"],"award-info":[{"award-number":["82561160165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105485","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:42:41Z","timestamp":1783698161000},"page":"105485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimizing CAR-T therapy in diffuse large B-cell lymphoma: Biological determinants and translational strategies across the therapeutic continuum"],"prefix":"10.1016","volume":"225","author":[{"given":"Yishan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105485_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105485_bib2","article-title":"Bioengineering the metabolic network of CAR T cells with GLP-1 and urolithin a increases persistence and long-term anti-tumor activity","volume":"6","author":"Akhtar","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib3","first-page":"749","article-title":"Folated-nanocarrier for paclitaxel drug delivery in leukemia cancer therapy","volume":"10","author":"Al-Musawi","year":"2018","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105485_bib4","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"key":"10.1016\/j.critrevonc.2026.105485_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105485_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105485_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41409-024-02427-8","article-title":"Role of bridging RT in relapsed\/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study","volume":"60","author":"Bramanti","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105485_bib9","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","article-title":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy","volume":"8","author":"Camus","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed\/Refractory B-Cell Non-hodgkin Lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11427-022-2173-9","article-title":"Loop CD20\/CD19 CAR-T cells eradicate B-cell malignancies efficiently","volume":"66","author":"Chen","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105485_bib12","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.ymthe.2025.02.012","article-title":"Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity","volume":"33","author":"Cheng","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib13","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2022-162594","article-title":"CAR T-Cell Therapy Remain Effective in Patients with Relapse\/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry","volume":"140","author":"Crochet","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib14","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.675179","article-title":"IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities","volume":"8","author":"Du","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105485_bib16","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2026.105485_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105485_bib19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105485_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","article-title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","volume":"17","author":"Ghilardi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41590-024-01847-4","article-title":"The BTLA\u2013HVEM axis restricts CAR T cell efficacy in cancer","volume":"25","author":"Guruprasad","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib23","article-title":"1\u03b1,25(OH)2D3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming","author":"He","year":"2025","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.critrevonc.2026.105485_bib24","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib25","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2022008697","article-title":"A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy","volume":"7","author":"Hirayama","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib26","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2025-2395","article-title":"Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R\/R DLBCL: An update analysis","volume":"146","author":"Hu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105485_bib29","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","article-title":"Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma","volume":"30","author":"Hubbeling","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105485_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Hubbeling","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","article-title":"Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy","volume":"59","author":"Iqbal","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2026.105485_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105485_bib33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s13402-023-00833-6","article-title":"Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma","volume":"46","author":"Jin","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.745286","article-title":"Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival","volume":"8","author":"Kalinin","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105485_bib35","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105485_bib36","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111258","article-title":"Bridging radiotherapy for chimeric antigen receptor T cells therapy in non-hodgkin lymphoma: Systematic review and meta-analysis","volume":"214","author":"Lam","year":"2026","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105485_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell. Discov."},{"key":"10.1016\/j.critrevonc.2026.105485_bib41","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OTT"},{"key":"10.1016\/j.critrevonc.2026.105485_bib42","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1\u2013positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105485_bib44","article-title":"\u03b2-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer","author":"Liu","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105485_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006287","article-title":"Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies","volume":"11","author":"Lopez","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105485_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","article-title":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","volume":"25","author":"Luo","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105485_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-025-02571-7","article-title":"Long-term follow-up demonstrates the curative potential of dual CD19\/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"11","author":"Mao","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-025-02571-7","article-title":"Long-term follow-up demonstrates the curative potential of dual CD19\/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"11","author":"Mao","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib52","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib53","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.cell.2026.01.015","article-title":"Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition","volume":"189","author":"Miller","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105485_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200914","article-title":"ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype","volume":"13","author":"Moreno-Cortes","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ymthe.2023.12.017","article-title":"Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7R\u03b1 expression","volume":"32","author":"Munoz","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib56","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib57","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10235-x","article-title":"vivo site-specific engineering to reprogram T cells","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105485_bib59","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib60","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2023-183034","article-title":"Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma: A Phase I\/II Study of Safety, Efficacy and Immune Correlative Analysis","volume":"142","author":"Poh","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib62","article-title":"Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: A multi-platform comparative study","volume":"15","author":"Ren","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105485_bib63","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy","volume":"14","author":"Rentsch","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105485_bib64","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","volume":"143","author":"Sakemura","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib67","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib68","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial <span>anti-CD19 CAR<\/span> T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a european center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70310","article-title":"Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma: A retrospective observational study","volume":"15","author":"Shen","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell. Metab."},{"key":"10.1016\/j.critrevonc.2026.105485_bib72","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105485_bib73","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/cells13060555","article-title":"Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation","volume":"13","author":"Su","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105485_bib75","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2025-2347","article-title":"SPPL3-glycosylation axis governs CD22 CAR T-cell susceptibility in B-ALL independent of antigen recognition","volume":"146","author":"Suh","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib76","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B cell lymphoma","author":"Tong","year":"2020","journal-title":"Blood Blood. 2020005278."},{"key":"10.1016\/j.critrevonc.2026.105485_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-022-00969-0","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","author":"Ueda","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105485_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113971","article-title":"Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells","volume":"147","author":"Wang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib80","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412070121","article-title":"Engineering bacteria for cancer immunotherapy by inhibiting IDO activity and reprogramming CD8+ T cell response","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105485_bib81","article-title":"Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed\/refractory DLBCL","volume":"17","author":"Wang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib82","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2023-186439","article-title":"Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib83","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol. Ther. - Methods & Clin. Dev."},{"key":"10.1016\/j.critrevonc.2026.105485_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-024-01986-y","article-title":"MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-fos and JunB","volume":"9","author":"Wang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib86","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00262-021-02895-7","article-title":"Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40\/4-1BB using oncolytic viral gene therapy","volume":"70","author":"Wenthe","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105485_bib87","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105485_bib88","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105485_bib89","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/bloodadvances.2022008294","article-title":"Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy","volume":"7","author":"Wudhikarn","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105485_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009212","article-title":"Bendamustine\u2013rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS\u2013STING activation in diffuse large B-cell lymphoma","volume":"12","author":"Xiao","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105485_bib91","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib92","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jtct.2025.07.018","article-title":"CD20CAR-T therapy preemptively treats patients with relapsed\/refractory DLBCL in partial remission after CD19CAR-T","volume":"31","author":"Xue","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2026.105485_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib94","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1182\/blood-2022-165174","article-title":"Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse\/Refractory Aggressive B-Cell Lymphoma","volume":"140","author":"Yu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib95","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer\u2013containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105485_bib96","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105485_bib97","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-024-06083-2","article-title":"The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma","author":"Zhang","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105485_bib98","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105485_bib99","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.omto.2023.08.009","article-title":"Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL","volume":"30","author":"Zhou","year":"2023","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:54:39Z","timestamp":1787108079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":99,"alternative-id":["S1040842826003720"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105485","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing CAR-T therapy in diffuse large B-cell lymphoma: Biological determinants and translational strategies across the therapeutic continuum","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105485"}}